D. Irlbeck

发表

Interplay between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity

R. Swanstrom, N. Parkin, Sook-Kyung Lee, 2011, Antimicrobial Agents and Chemotherapy.

Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors

Wolfgang Resch, R. Swanstrom, D. Irlbeck, 2003, Antimicrobial Agents and Chemotherapy.

Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals

C. Labranche, K. Kitrinos, D. Irlbeck, 2008, AIDS.

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data

B. Ha, D. Irlbeck, E. Dejesus, 2010, The open AIDS journal.

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens

D. Gibb, D. Irlbeck, M. Ait-Khaled, 2004, HIV medicine.

Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles

Philip R. Johnson, R. Johnston, D. Montefiori, 2000, Journal of Virology.

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

N. Parkin, D. Irlbeck, L. Trinh, 2009, The Journal of infectious diseases.

Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine

J. Bartlett, D. Irlbeck, N. Sosa, 2006, Journal of acquired immune deficiency syndromes.

Salvage Therapy With Abacavir and Other Reverse Transcriptase Inhibitors for Human Immunodeficiency-Associated Encephalopathy

O. Ramilo, D. Irlbeck, M. D. de José, 2006, The Pediatric infectious disease journal.

Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy

Michael Monsour, Paul Sandstrom, W. Heneine, 2008, PLoS medicine.

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo

B. Strahl, A. Sanchez, R. Prinjha, 2022, The Journal of clinical investigation.

No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank

James R. Brown, N. Klimas, S. Vernon, 2014, BMC Research Notes.

Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo

B. Liao, Corbin D. Jones, J. Lifson, 2020, Nature.

Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector

R. Johnston, J. Frelinger, M. Betts, 1997, Journal of virology.

Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth

J. Routy, K. Karwacz, A. Fassati, 2021, Proceedings of the National Academy of Sciences.

The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance.

R. Swanstrom, D. Irlbeck, R. Coombs, 1999, AIDS research and human retroviruses.

Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms.

C. McDanal, D. Irlbeck, Stacey A. Jones, 2017, Bioorganic & medicinal chemistry letters.

Synthesis and Biological Evaluation of Macrocyclized Betulin Derivatives as a Novel Class of Anti-HIV-1 Maturation Inhibitors

Heping Yang, C. McDanal, D. Irlbeck, 2014, The open medicinal chemistry journal.

Virologic Failure in Therapy-Naïve Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope

J. Word, K. Kitrinos, D. Irlbeck, 2008, Antimicrobial Agents and Chemotherapy.

The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent

Corbin D. Jones, J. Routy, D. Margolis, 2018, bioRxiv.

Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles

Philip R. Johnson, R. Johnston, D. Montefiori, 2000, Journal of Virology.

Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism

K. Kitrinos, D. Irlbeck, H. Amrine-Madsen, 2008, Antimicrobial Agents and Chemotherapy.